Current Effective Therapeutics in Management of COVID‐19

Kavya Atluri, Iris Aimlin, Shitij Arora

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


The current pandemic due to the SARS‐CoV‐2 virus has caused irreparable damage glob-ally. High importance is placed on defining current therapeutics for Coronavirus Disease 2019 (COVID‐19). In this review, we discuss the evidence from pivotal trials that led to the approval of effective therapeutics in the treatment and prevention of COVID‐19. We categorize them as effective outpatient and inpatient management strategies The review also attempts to contextualize the efficacy of therapeutics to the emerging variants. Vaccines, which remain the most effective prevention against hospitalization and deaths is not included in this review.

Original languageEnglish (US)
Article number3838
JournalJournal of Clinical Medicine
Issue number13
StatePublished - Jul 1 2022


  • Anakinra
  • Anticoagulation
  • COVID‐19
  • Casirivimab plus imdevimab
  • Evusheld
  • Paxlovid
  • Remdesivir
  • Sotrovimab
  • baricitinib
  • bebtelovimab
  • coronavirus disease 2019
  • corticosteroids
  • molnupiravir
  • monoclonal antibodies
  • omicron
  • therapeutics
  • timeline
  • tocilizumab

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Current Effective Therapeutics in Management of COVID‐19'. Together they form a unique fingerprint.

Cite this